Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
20022.2k citationsMark E. Dudley, John R. Wunderlich et al.Scienceprofile →
A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
20032.1k citationsJames Chih‐Hsin Yang, Leah Haworth et al.profile →
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
20062.0k citationsRichard A. Morgan, Mark E. Dudley et al.Scienceprofile →
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
20111.6k citationsSteven A. Rosenberg, James Chih‐Hsin Yang et al.Clinical Cancer Researchprofile →
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
20031.2k citationsGiao Q. Phan, James Chih‐Hsin Yang et al.Proceedings of the National Academy of Sciencesprofile →
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells
20111.1k citationsMark E. Dudley, Steven A. Feldman et al.profile →
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
20081.0k citationsMark E. Dudley, James Chih‐Hsin Yang et al.Journal of Clinical Oncologyprofile →
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
2010954 citationsRichard E. Royal, Catherine Lévy et al.Journal of Immunotherapyprofile →
T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
2010791 citationsJames C. Yang, Russell C. Langan et al.profile →
Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4
2005771 citationsGiao Q. Phan, Martha Quezado et al.Journal of Clinical Oncologyprofile →
Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4
2006646 citationsJoseph Blansfield, Khoi Q. Tran et al.Journal of Clinical Oncologyprofile →
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
2014585 citationsPaul F. Robbins, Sadik H. Kassim et al.Clinical Cancer Researchprofile →
Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
2003573 citationsJames Chih‐Hsin Yang, Richard M. Sherry et al.Journal of Clinical Oncologyprofile →
Phase I Study of the Intravenous Administration of AttenuatedSalmonella typhimuriumto Patients With Metastatic Melanoma
2002565 citationsJohn Toso, Vee J. Gill et al.Journal of Clinical Oncologyprofile →
Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis
2007537 citationsJames Chih‐Hsin Yang, Marybeth S. Hughes et al.Journal of Immunotherapyprofile →
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
2007519 citationsJacob A. Klapper, Franz O. Smith et al.Clinical Cancer Researchprofile →
Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells
2015506 citationsSanja Stevanović, Lindsey M. Draper et al.Journal of Clinical Oncologyprofile →
Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma
2019301 citationsStephanie L. Goff, Richard A. Morgan et al.Journal of Immunotherapyprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Richard M. Sherry
Since
Specialization
Citations
This map shows the geographic impact of Richard M. Sherry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard M. Sherry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard M. Sherry more than expected).
Fields of papers citing papers by Richard M. Sherry
This network shows the impact of papers produced by Richard M. Sherry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard M. Sherry. The network helps show where Richard M. Sherry may publish in the future.
Co-authorship network of co-authors of Richard M. Sherry
This figure shows the co-authorship network connecting the top 25 collaborators of Richard M. Sherry.
A scholar is included among the top collaborators of Richard M. Sherry based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Richard M. Sherry. Richard M. Sherry is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Stevanović, Sanja, Lindsey M. Draper, Michelle M. Langhan, et al.. (2015). Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells. Journal of Clinical Oncology. 33(14). 1543–1550.506 indexed citations breakdown →
Robbins, Paul F., Sadik H. Kassim, Thai L.N. Tran, et al.. (2014). A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response. Clinical Cancer Research. 21(5). 1019–1027.585 indexed citations breakdown →
Rosenberg, Steven A., James Chih‐Hsin Yang, Richard M. Sherry, et al.. (2011). Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. Clinical Cancer Research. 17(13). 4550–4557.1603 indexed citations breakdown →
Dudley, Mark E., James Chih‐Hsin Yang, Richard M. Sherry, et al.. (2008). Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens. Journal of Clinical Oncology. 26(32). 5233–5239.1017 indexed citations breakdown →
13.
Blansfield, Joseph, Khoi Q. Tran, Andrew L. Feldman, et al.. (2006). Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4. Journal of Clinical Oncology. 24(15). 2283–2289.646 indexed citations breakdown →
14.
Morgan, Richard A., Mark E. Dudley, John R. Wunderlich, et al.. (2006). Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. Science. 314(5796). 126–129.1961 indexed citations breakdown →
Phan, Giao Q., James Chih‐Hsin Yang, Richard M. Sherry, et al.. (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences. 100(14). 8372–8377.1234 indexed citations breakdown →
Toso, John, Vee J. Gill, Patrick Hwu, et al.. (2002). Phase I Study of the Intravenous Administration of AttenuatedSalmonella typhimuriumto Patients With Metastatic Melanoma. Journal of Clinical Oncology. 20(1). 142–152.565 indexed citations breakdown →
20.
Sherry, Richard M., et al.. (1992). Embolization of a hepatoportal fistula in a patient with Ehlers-Danlos syndrome and colon perforation.. PubMed. 111(4). 475–8.19 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.